SavedAdd your journal

Journals / Eurasian Journal of Biological and Chemical Sciences / 2022 / Cilt: 5 - Sayı: 2

Thymoquinone Prevents Valproic Acid-Induced Nephrotoxicity in Rat Kidney

Sebile AZİRAK
Deniz TAŞTEMİR KORKMAZ
Sedat BİLGİÇ
Meltem ÖZGÖÇMEN
Mehmet Kaya ÖZER
Pages
77–84
Publication Date
2022-12-28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

TQ protects the kidney against the toxic effects of VA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Valproic acid (VA), widely used as an antiepileptic, causes structural and functional kidney disorders.
📊
Key Findings & Data:Twenty-one male Spraque Dawley rats were grouped into control, VA, and VA + TQ groups (n=7 for per group).
💡
Conclusion & Impact:TQ protects the kidney against the toxic effects of VA.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Apoptosis · COX-1 · COX-2

Abstract

Valproic acid (VA), widely used as an antiepileptic, causes structural and functional kidney disorders. Whether thymoquinone (TQ) has a beneficial effect on valproic acid (VA)-induced nephrotoxicity has been investigated. Twenty-one male Spraque Dawley rats were grouped into control, VA, and VA + TQ groups (n=7 for per group). VA (500 mg/kg/day) and TQ (50 mg/kg/day) were applied to the rats orally for 14 days. They were euthanized on the 15th day of the treatment. The cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) gene expression levels, biochemical parameters, total antioxidant/oxidant statuses (TAS/TOS), oxidative stress index (OSI), histological and immunohistochemical analysis were performed to evaluate kidney toxicity. In the VA + TQ group, COX-1 expression levels increased, while COX-2 expression levels decreased. While the creatinine (Cr) and blood urea nitrogen (BUN) levels, production of caspase-3 (CAS-3) and NADPH oxidase-4 (NOX-4) were increased in the VA-treated group, they were decreased in VA + TQ group. Treatment with TQ against VA administration decreased TOS and OSI levels while increasing TAS. TQ protects the kidney against the toxic effects of VA.

🔖

Cite This Article

AZİRAK, S., KORKMAZ, D. T., BİLGİÇ, S., ÖZGÖÇMEN, M., ÖZER, M. K. (2022). Thymoquinone Prevents Valproic Acid-Induced Nephrotoxicity in Rat Kidney. Eurasian Journal of Biological and Chemical Sciences, Cilt: 5 - Sayı: 2, 77–84. https://ajindex.com/articles/868010

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Abdel-Wahhab MA, Nada SA, Arbid MS. 1999. Ochratoxicosis: prevention of developmental toxicity by L-methionine in rats. J Appl Toxicol. 19(1): 7-12.
  2. Altunbaşak S, Yildizaş D, Anarat A, Burgut HR. 2001. Renal tubular dysfunction in epileptic children on valproic acid therapy. Pediatr Nephrol. 16(3): 256-259. Asconapé JJ. 2014. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol. 119: 417-432.
  3. Atta MS, Almadaly EA, El-Far AH, Saleh RM, Assar DH, Jaouni SKA, Mousa SA. 2017. Thymoquinone Defeats Diabetes-Induced Testicular Damage in Rats Targeting Antioxidant, Inflammatory and Aromatase Expression. Int J Mol Sci. 18(5): 919. Azirak S, Bilgiç S, Taştemir Korkmaz D, Sevimli M, Özer MK. 2022. Effect of thymoquinone on ameliorating valproic acid-induced damage in pancreatic tissue of rats. Cukurova Med J. 47: 350-359.
  4. Badary OA, Abdel-Naim AB, Abdel-Wahab MH, Hamada FM. 2000. The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats. Toxicology. 143(3): 219-226.
  5. Barbalho PG, Carvalho BS, Lopes-Cendes I, Maurer-Morelli CV. 2016. Cyclooxygenase-1 as a Potential Therapeutic Target for Seizure Suppression: Evidences from Zebrafish Pentylenetetrazole-Seizure Model. Front Neurol. 7: 200. Barrett CE, Hennessey TM, Gordon KM, Ryan SJ, McNair ML, Ressler KJ, Rainnie DG. 2017. Developmental disruption of amygdala transcriptome and socioemotional behavior in rats exposed to valproic acid prenatally. Mol Autism. 8: 42. Bilgiç S, Korkmaz DT, Azirak S, Güvenç AN, Kocaman N, Özer MK. 2017. Risperidone-Induced Renal Damage and Metabolic Side Effects: The Protective Effect of Resveratrol. Oxid Med Cell Longev. 8709521. Blumenfeld A, Gennings C, Cady R. 2012. Pharmacological synergy: the next frontier on therapeutic advancement for migraine. Headache. 52(4): 636-647. Chang TK and Abbott FS. 2006. Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab Rev. 38(4): 627-639. Cole-Edwards KK and Bazan NG. 2005. Lipid signaling in experimental epilepsy. Neurochem Res. 30(6-7): 847-853. Crofford LJ. 1997. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl. 49:15-19. de Leval X, Delarge J, Somers F, de Tullio P, Henrotin Y, Pirotte B, Dogné JM. 2000. Recent advances in inducible cyclooxygenase (COX-2) inhibition. Curr Med Chem. 7(10):1041-1062. Dhir A. 2019. An update of cyclooxygenase (COX)-inhibitors in epilepsy disorders. Expert Opin Investig Drugs. 28(2):191-205. Eirin A